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ABCB1 efflux pump (P-glycoprotein)In previous studies, 56 novel selenoesters and one cyclic selenoanhydride with chemopreventive,
antiproliferative and cytotoxic activity were described. Herein, the selenoanhydride and selected
selenoesters were evaluated for their ability to reverse the cancer multidrug resistance (MDR) using
the ABCB1 efflux pump inhibition assay in mouse MDR T-lymphoma cells. Results showed that the
selenoanhydride (1) and the selenoesters with ketone terminal fragments (9–11) exerted (1.7–3.6)-fold
stronger efflux pump inhibitory action than the reference verapamil. In addition, those four derivatives
triggered apoptotic events in more than 80% of the examined MDR mouse cells.
 2016 Elsevier Ltd. All rights reserved.Selenium and its organic and inorganic derivatives fulfil several
vital biological functions.1 Interest in selenium has arisen since the
discovery of the fact that its deficiency can cause clinical disorders,
e.g., the diseases of Keshan and Kashin-Beck.2 Afterwards, epidemi-
ological studies reported by Li in China3 and Clark in USA4,5
proposed that the dietary supplementation with selenium reduced
the incidence of lung, oesophagus4 and prostate5 cancer. The pub-
lication of those results initiated an intense and productive search
of novel inorganic and organic selenocompounds with chemopre-
ventive, antiproliferative and cytotoxic activity against cancer.6–9
Among the inorganic selenium-containing salts, sodium selenite
could be highlighted for its anticancer properties10 whereas several
of the most known organic selenocompounds with anticancer
properties are methylselenol,11,12 methylseleninic acid,13,14 seleno-
cyanates15,16 and diphenyldiselenide.17,18 Selenium nanoparticles
are also being deeply studied, both in cancer field19,20 and in cancer
or bacterial multidrug resistance.21,22
Considering these antecedents, our previous studies concerned
the design, synthesis and biological evaluation of selenium-containing anticancer agents, including 56 selenoesters and one
selenoanhydride.23,24 Those organoselenic derivatives displayed
significant cytostatic action with IG50 values in nanomolar ranges,
whereas the LD50 values of the most cytotoxic selenocompounds
were in the micromolar range.23,24 Various lines of evidence25–29
indicate that selenocompounds enhance synergistically the activity
of anticancer drugs when they are administered in combination.
Thus, synergistic effects over the anticancer activity have been
observed in the following selenocompounds and anticancer drug
combinations: diphenylmethyl selenocyanate and cisplatin in a
murine tumor model,25 selenium nanoparticles and irinotecan in
HCT-8 colon cancer cells,26 selenite and imatinib in HCT116 col-
orectal cancer cells,27 selenocysteine and auranofin in A549 lung
cancer cells;28 and methylseleninic acid and paclitaxel in a murine
cancer model.29 The synergistic effects observed suggest multidrug
resistance (MDR) reversing activity for the selenocompounds. The
MDR against the chemotherapeutic drugs action is a worrying prob-
lem in cancer treatment.30,31 Among the different mechanisms
involved in the cancer MDR processes, the increased activity of
the efflux pumps is one of the most common.32 The membrane
transport proteins, especially the P-glycoprotein (P-gp, ABCB1
Table 2
Effects of selenocompounds on rhodamine 123 retention by L5178Y multidrug
resistant (MDR) mouse T-lymphoma cells
Sample Concentration (lM) FARa FAR quotientb (%)
Verapamil 20 27.4 100
1 2 43.14 157.4
1 20 97.61 356.2
2 2 0.99 3.61
2 20 1.07 3.19
3 2 1.13 3.98
3 20 1.49 5.44
4 2 0.93 2.78
4 20 0.98 3.39
5 2 3.97 18.64
5 20 3.09 14.49
6 2 1.02 3.04
6 20 1.05 3.72
7 2 6.45 30.28
7 20 8.53 23.54
8 2 0.65 3.05
8 20 5.68 2.37
9 2 94.20 343.79
9 20 84.64 308.91
10 2 9.28 33.87
10 20 48.67 177.63
11 2 12.56 45.84
11 20 46.35 169.16
DMSO 2% 0.76 2.77
a FAR: fluorescence activity ratio, calculated as follows:
FAR ¼ MDRtreated=MDRcontrol
parentaltreated=parentalcontrol
: ð1Þ
b Calculated as follows:
Quotient ¼ FARcompound
FARverapamil
 100: ð2Þ
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cules out of the cell.32,33 This is a natural protective mechanism of
the cells against the action of toxic compounds that is stimulated
in cancer cells.
Thus, the design of inhibitors of the efflux pumps, especially of
the ABCB1, is a promising strategy in cancer therapy. For the
evaluation of the efflux-pump related resistance in cancer, cell
lines with over-expressed efflux pump systems, such as ABCB1,
are commonly used.34
In this context, we have selected the representative structures
1–11 (Table 1) among the selenocompounds previously reported
in Refs. 23,24 to investigate their capacity to reverse the cancer
MDR via the inhibition of the efflux pump ABCB1. The representa-
tive compounds contain a selenoanhydride (1) or a selenoester
(2–11) functional group. The alkyl moiety bounded to the selenium
atom in the selenoesters is a methyl group (2–5) or includes sec-
ondary functional groups, such as: amides (6), carboxylic esters
(7–8) or ketones (9–11). The compounds were resynthesized in
the amount required to perform the biological assays, using the
methods described earlier.23,24 They were examined on the follow-
ing biological actions: (i) inhibition of ABCB1 via the fluorescent
substrate retention assay, (ii) cytotoxicity in the MTT assay and
(iii) their capacity to induce apoptotic processes.
The biological studies were performed in two cell lines, the
parental L5178Y and the MDR-derived mouse T-lymphoma cells
transfected with the human MDR1 (ABCB1) gene that codes for
the ABC transporter ABCB1.35
The efflux modulating effects of compounds 1–11 were investi-
gated in the MDR cancer cells (mouse T-lymphoma) using the
rhodamine 123 accumulation assays.34–37 Rhodamine 123 is the
dye–substrate for ABCB1. The percentage of mean fluorescence
intensity was calculated for the treated MDR cells in comparison
with the untreated cells. Results, expressed as the fluorescence
activity ratio (FAR), have been compared to the action of the refer-
ence verapamil by the FAR quotient. The FAR and quotient values
were computed according to the Eqs. 1 and 2, respectively (Table 2).
Results indicated that the selenoesters 2–8 slightly affected the
efflux activity of ABCB1, whereas the compounds 1 and 9–11
(Fig. 1) displayed a pronounced modulating action on this efflux
pump in the MDR mouse T-lymphoma cells. It is noteworthy that
derivatives 1 and 9 inhibited the ABCB1 pump (1.6–3.4)-fold stron-
ger than the reference inhibitor (verapamil) at its 10-fold higherTable 1
Structure of the selenocompounds evaluated as MDR reversing agents
Compd Group R1 X n R2
1 A — — — —
2 B 5-COSeCH3 S 0 ACH3
3 B 6-COSeCH3 N 1 ACH3
4 B 3-COSeCH3 C 1 ACH3
5 B 4-COSeCH3 C 1 ACH3
6 B AH C 1 ACH2CONH2
7 B 4-Cl C 1 ACH2COOCH3
8 B AH C 1 ACH2COOPh
9 B 4-Cl C 1 ACH2COCH3
10 B 4-Cl C 1 ACH2COC(CH3)3
11 B 3,5-DiOCH3 C 1 ACH2COC(CH3)3
Compd: Compound.
Figure 1. Structure of the most active selenocompounds.concentration. When evaluated at the same concentration than
verapamil, compounds 1 and 9–11 inhibited this efflux pump
(1.7–3.6)-fold stronger than this known inhibitor.
The cytotoxic effects of the selenocompounds 1–11 were deter-
mined and compared with the action exerted by two reference
drugs with moderate (thioridazine) or weak (verapamil) cytotoxi-
city. Results were expressed as IC50 values (Table 3). Six com-
pounds (2, 4–8) were less cytotoxic than both reference drugs.
However, the most active compounds (1 and 9–11) showed a sig-
nificantly higher cytotoxicity than thioridazine and verapamil in
both cell lines. Besides, the selenoesters 9–11 exhibited their cyto-
toxic action in the nanomolar range at least in one of the two
mouse T-lymphoma cell lines investigated. In the case of the most
active one (10), the IC50 value was 430 nM in the MDR cells.
Table 3
Cytotoxic effects of selenocompounds on L5178Y parental (PAR) and multidrug
resistant (MDR) mouse T-lymphoma cells
Compd PAR mouse T-lymphoma
cells
MDR mouse
T-lymphoma cells
IC50 (lM) SD± IC50 (lM) SD±
1 3.97 1.26 4.65 0.71
2 >100 — >100 —
3 19.5 2.10 16.9 3.23
4 >100 — >100 —
5 >100 — >100 —
6 >100 — 36.4 9.91
7 >100 — 87.8 5.54
8 >100 — >100 —
9 0.78 0.17 1.03 0.31
10 0.94 0.11 0.43 0.25
11 1.31 0.12 0.97 0.28
VP >100 — 47.85 1.88
TZ 12.72 0.56 7.43 0.68
Compd: compound, VP: verapamil, TZ: thioridazine, DMSO: dimethyl-sulfoxide.
E. Domínguez-Álvarez et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2821–2824 2823The capacity of the selenocompounds 1–11 to induce apoptosis
in mouseMDR and PAR cells (Table 4) wasmeasured at the concen-
tration of 2 lM. The apoptosis inducer 12H-benzo[a]phenothiazine
(M627) was used as positive control at the concentration of
20 lM.37 In accordance with previous assays, only compounds 1
and 9–11 caused significant apoptotic events, whereas the remain-
ing compounds (2–8) were inactive. The compounds 1, 10, and 11
proved to exert early apoptosis-inducing activity in ABCB1 over-
expressing mouse MDR T-lymphoma cells, being the proportion
of early apoptosis 32.2%, 15.9%, and 16.6%, respectively. In addition,
they triggered late apoptosis or necrosis in the 45.0%, 21.9%, and
30.5 % of the treated cell population, respectively. Compound 9
induced late apoptosis in the 85.8% of the cell population. If we con-
sider the early and late apoptosis/necrosis together, derivatives 1
and 9–11 induced apoptosis in the 77.2%, 90.6%, 47.8% and 47.1%
of cells, respectively. Interestingly, it was demonstrated the same
order of activity as that observed in the ABCB1 inhibition assay.
The selenoesters (2–8) were significantly less pro-apoptotic as they
triggered these cell death processes in less than 10% of cells studied.
Thus, 1 was the most pro-apoptotic compound within the tested
series. It demonstrated an apoptosis induction close to the positive
control (M627; 93.6%) at a 10-fold lower concentration.
Alternatively, the selenium derivatives (1 and 9–11) induced
early apoptosis events on the parental mouse PAR T-lymphoma
cells in the range of 30% of the analyzed cells for 1, 9 and 10;
and of 15% for 11 (Table 4). Late apoptosis and necrosis were trig-
gered by these compounds in the range of 53–67% of the cells eval-
uated. In this cell line, the four active compounds (1 and 9–11)
triggered apoptotic events in more than 80% of the cells evaluated,
what was much higher than the apoptotic induction exerted by the
positive control of 12H-benzo[a]phenothiazine (57%) at a 10-fold
higher concentration. The remaining selenoesters tested (2–8)
induced apoptotic events in the range from 5% to 14% of the
analyzed cells.
Seven out of the eleven selenocompounds evaluated were more
pro-apoptotic in PAR cells than in MDR cells. This experimental
fact seems to be related to the more intensive expelling of the com-
pounds by the ABCB1 efflux pump in the case of the multidrug
resistant cells. These pumps are over-expressed in the MDR cells,
whereas their level is much lower in the PAR cells. Consequently,
the parental cells expel out a minor percentage of the selenocom-
pounds, allowing them to trigger a stronger pro-apoptotic action
on the cell. The collaboration between apoptotic and ABCB1 mod-
ulating actions can be observed for the active compounds 10 and
11. These two derivatives modulated weakly the ABCB1 pump at
2 lM (10 and 11, Table 2) and demonstrated an almost 2-folddecrease of the apoptotic effects in the MDR T-lymphoma cells.
In contrast, the compounds that strongly modulated the efflux
pump at a 2 lM concentration (1 and 9, Table 2) showed also a
strong apoptosis induction in MDR cells, reducing thus the diver-
gence of their total apoptotic action between parental and MDR
cells to a percentage below 10% (Table 4). The observed differential
action could be explaining considering that compounds 10 and 11
exerted a partial inhibition of the efflux pumps at the assayed con-
centration, enabling in this way the expelling out of the cell of a
fraction of the apoptotic compound. This would reduce the concen-
tration of the selenocompound inside the cell, thus reducing its
apoptotic induction.
The results obtained within the different biological assays
allowed us to perform a structure–activity relationship analysis
for the tested series of selenocompounds (1–11). The active com-
pounds are the same in all the assays: the selenoanhydride 1 and
the selenoesters 9–11. The investigated cytotoxic activity seems
to depend on the chemical variation at the alkyl chain directly
bounded to selenium atom. The tert-butyl (10, 11) or methyl (9)
ketones seem to be the most profitable, whereas ester (7, 8), amide
(6) or methyl (4, 6) groups decrease significantly the cytotoxicity in
both parental and MDR mouse T-lymphoma cells. These SAR are in
concordance with the results reported in previous cytotoxicity
studies in different cancer cell lines.23 The observed variations of
the activity with the change of the functional group can be related
with the modulation of the polarity of the molecule exerted by this
functional group at the alkyl moiety, as well as with the modula-
tion of the hydrolysis rate of the selenoester; as hypothesized
earlier.23
The role of the substituents at the aromatic ring seems to be less
important for the cytotoxicity but it can be noticeable, too. In the
case of the most active selenoesters (9 and 10), the aromatic
phenyl ring has a chlorine atom at para position. The replacement
of this 4-chlorophenyl moiety of 10 by the 3,5-dimethoxyphenyl
one (11) caused an almost 2-fold reduction of the cytotoxic activity
in both cell lines studied (Table 3).
The SAR analysis for the rhodamine 123 retention studies
(Table 2) is in analogy with that for the cytotoxicity assay. Results
of the efflux modulating effects in comparison with the structures
of compounds 1–11 highlight the importance of the aforesaid
structural features, including: the ketone in the Se-alkyl moiety
(9–11) and the cyclic selenoanhydride (1). However, the compound
containing a methyl ketone (9) was the most potent ABCB1
inhibitor, better than the selenoanhydride (1), and both of them
affected more this efflux pump than the compounds with the
tert-butylketone terminate fragment (10, 11). In the case of the
apoptosis-inducing activity assays, the SAR analysis is in high
compatibility with that of the rhodamine 123 retention tests.
The beneficial role of the selenoanhydride (1) and methyl
ketone selenoester moiety (9) is unquestionable on the basis of
the most potent apoptotic effects, in the range of the reference
M627 or higher, that can be noted for these structures in both
PAR and MDR cell lines. The presence of tert-butylketone ends
(10, 11) seems to be especially profitable for the apoptotic effects
in parental T-lymphoma cells, whereas a replacement of the ketone
fragment with ester-, amide- or methyl one (2–8) causes a huge
loss of the activity (Table 4).
In conclusion, these studies allowed us to identify four deriva-
tives (1, 9–11), out of the eleven tested selenocompounds, that
demonstrated high potency to inhibit cancer MDR efflux pump
ABCB1 with simultaneous cytotoxic- and strong pro-apoptotic
activities in the mouse T-lymphoma cells. Results of the biological
assays suggest a synergistic mechanism of the pro-apoptotic and
the efflux pump inhibitory actions for the active compounds (1,
9–11). The active agents found belong to two following families
of selenocompounds: the benzoselenophene-diones (1) and the
Table 4
Apoptosis-inducing activity of selenocompounds in MDR and in PAR mouse T-lymphoma cells, after 1 h of incubation
Concn
(lM)
Gated events in mouse MDR T-lymphoma cells Gated events in mouse PAR T-lymphoma cells
Early
apoptosis (%)
Late apoptosis,
necrosis (%)
Cell death
(%)
Total apoptotic
events
Early
apoptosis (%)
Late apoptosis,
necrosis (%)
Cell death
(%)
Total apoptotic
events
A I — 0 0 0 0 0.217 0 0 0.217
A I+ — 0.015 0.01 2.18 0.025 0.085 1.14 1.55 1.225
A+ I — 4.35 0 0 4.35 4.27 0.02 0 4.29
A+ I+ — 2.2 1.57 0.03 3.77 2.60 0.818 0.12 3.418
DMSO 2% 6.46 2.28 0.09 8.74 3.96 0.859 0.191 4.819
M627 20 47.9 45.7 0.12 93.6 51.2 5.58 0.279 56.78
1 2 32.2 45 0.47 77.2 31.5 53.9 0.767 85.4
2 2 5.07 2.34 0.30 7.41 6.64 6.93 0.352 13.57
3 2 5.38 3.28 0.24 8.66 5.97 7.18 0.202 13.15
4 2 4.35 2.8 0.45 7.15 4.47 3.79 0.076 8.26
5 2 3.01 3.25 0.37 6.26 3.61 2.01 0.110 5.62
6 2 3.01 2.91 0.33 5.92 2.46 2.24 0.081 4.70
7 2 2.69 1.47 0.03 4.16 5.09 2.52 0.497 7.61
8 2 3.90 2.26 0.16 6.16 3.00 2.11 0.240 5.11
9 2 3.86 85.8 7.66 90.6 30.8 52.7 0.874 83.5
10 2 15.9 21.9 1.21 47.8 36.1 56.1 0.255 92.1
11 2 16.6 30.5 0.51 47.1 15.7 66.6 0.167 82.3
A+: Annexin V-FITC staining, A: without Annexin V-FITC, I+: propidium iodide staining, I: without propidium iodide.
Concn: Concentration; M627: 12H-benzo[a]phenothiazine. ‘Total apoptotic events’ is the sum of ‘early apoptosis’ and ‘late apoptosis, necrosis’.
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that a ketone moiety, bounded to selenium in the selenoesters
through a methylene bridge, plays a crucial role for the expected
pro-apoptotic/ABCB1 inhibitory properties. The promising activity
of derivatives 1 and 9–11 could be of future interest in oncology.
The compounds benzo[c]selenophene-1,3-dione (1) and Se-2-
oxopropyl 4-chlorobenzoselenoate (9) will be selected as two
parallel lead-structures for further search of pro-apoptotic cancer
MDR modulators among selenium containing compounds.
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